Clinical Trial Update: A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine [Phase 3]

View source ↗

Summary

Phase 3 study evaluating tapentadol (CG5503) for chronic tumor-related pain vs placebo and morphine; terminated with posted results in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neoplasm
• Pain

Drugs mentioned

• Tapentadol (Tapentadol hydrochloride)

Snippet

Sponsor: Grünenthal GmbH | Conditions: Pain, Neoplasm | Phase 3 | Status: TERMINATED | Results posted: 2010-07-02